Hematology and Oncology

New leaders named to Vanderbilt-Ingram research programs

Read more about New leaders named to Vanderbilt-Ingram research programs

Seven new leaders have been appointed to guide Vanderbilt-Ingram Cancer Center’s research programs. Martha Shrubsole, PhD (Epidemiology), joins Xiao-Ou Shu, MD, PhD, MPH, Ingram Professor of Cancer Research (Epidemiology), as a co-leader of the Cancer Epidemiology Research Program. Vandana Abramson, MD (Hematology and Oncology), joins Justin Balko, PharmD, PHD (Hematology and Oncology), as a co-leader of the Breast Cancer Research Program.

Eden Biltibo is Multiple Myeloma Research Foundation scholar recipient

Read more about Eden Biltibo is Multiple Myeloma Research Foundation scholar recipient

Vanderbilt’s Eden Biltibo, MD, MS, is one of the first recipients of the Multiple Myeloma Research Foundation’s Scholars Program, an initiative launched in 2022.

Vanderbilt’s Dr. W. Kimryn Rathmell to be appointed director of the National Cancer Institute

Read more about Vanderbilt’s Dr. W. Kimryn Rathmell to be appointed director of the National Cancer Institute

Kimryn Rathmell, MD, PhD, MMHC, the Hugh Jackson Professor of Medicine and chair of the Department of Medicine at Vanderbilt University Medical Center (VUMC), will be appointed Director of the National Cancer Institute (NCI).

VUMC’s Kimryn Rathmell, MD, PhD, wins Doris Duke Foundation Paragon Award

Read more about VUMC’s Kimryn Rathmell, MD, PhD, wins Doris Duke Foundation Paragon Award

Kimryn Rathmell, MD, PhD, chair of the Department of Medicine at Vanderbilt University Medical Center, has received the Paragon Award for Research Excellence from the Doris Duke Foundation (DDF).

Vanderbilt-Ingram Cancer Center earns NCI Merit Award

Read more about Vanderbilt-Ingram Cancer Center earns NCI Merit Award

Vanderbilt-Ingram Cancer Center (VICC) has earned a Merit Extension Award from the National Cancer Institute (NCI) in recognition of more than a decade of sustained exceptional progress.

Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

Read more about Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors

A subset of side effects continued to improve over time,” said the study’s senior author, Douglas Johnson, MD, MSCI, clinical director of melanoma at Vanderbilt-Ingram Cancer Center and holder of the Susan and Luke Simons Directorship.

Study finds hallmarks of T cell exhaustion within hours of tumor exposure

Read more about Study finds hallmarks of T cell exhaustion within hours of tumor exposure

"Surprising findings have implications for cancer immunotherapies that aim to harness the tumor-killing power of T cells, and they challenge existing ideas about how T cells become exhausted", said Mary Philip, MD, PhD, assistant professor of Medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center.

Grand rounds event highlights Advanced Practice Nursing at Vanderbilt

Read more about Grand rounds event highlights Advanced Practice Nursing at Vanderbilt

Advanced practice nurses, physician assistants and Medical Center leaders gathered in Light Hall on Jan. 17 for the kickoff of the 2023 series of Advanced Practice Grand Rounds, a monthly educational series organized by the Vanderbilt University Medical Center Office of Advanced Practice.

Trial seeks to expand therapies for biliary cancers

Read more about Trial seeks to expand therapies for biliary cancers

A Vanderbilt physician is leading a clinical trial that aims to unleash the full potential of immunotherapies against biliary tract cancers (BTC), which include cholangiocarcinoma and gallbladder cancer. Treatment options have been limited for BTC, which have low survival rates similar to pancreatic cancer. However, after a decade, there has been a paradigm shift in treating patients with BTC who are not eligible to have their cancer surgically removed.

Targeted therapy for neuroendocrine tumors

Read more about Targeted therapy for neuroendocrine tumors

Neuroendocrine tumors (NETs) can develop in many organs, with the pancreas a frequent location. These tumors are often cancerous and potentially fatal, and some NETs produce hormones causing a variety of symptoms.